Cargando…

Clinical Efficacy of Temocillin Standard Dosing in Patients Treated with Outpatient Antimicrobial Therapy

In 2020, EUCAST introduced breakpoints for temocillin. Based on these guidelines, reporting of temocillin susceptibility of Enterobacterales in the context of complicated urinary tract infections (cUTI) implicates the use of a high dose of temocillin (2 g q8h) constantly. We aimed to evaluate the cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Van den Broucke, Evelyne, Thijs, Lore, Desmet, Stefanie, Vander Elst, Lotte, Gijsen, Matthias, Mylemans, Marnix, Van de Gaer, Otto, Peetermans, Willy E., Quintens, Charlotte, Spriet, Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699557/
https://www.ncbi.nlm.nih.gov/pubmed/36365108
http://dx.doi.org/10.3390/pharmaceutics14112289
_version_ 1784839103341133824
author Van den Broucke, Evelyne
Thijs, Lore
Desmet, Stefanie
Vander Elst, Lotte
Gijsen, Matthias
Mylemans, Marnix
Van de Gaer, Otto
Peetermans, Willy E.
Quintens, Charlotte
Spriet, Isabel
author_facet Van den Broucke, Evelyne
Thijs, Lore
Desmet, Stefanie
Vander Elst, Lotte
Gijsen, Matthias
Mylemans, Marnix
Van de Gaer, Otto
Peetermans, Willy E.
Quintens, Charlotte
Spriet, Isabel
author_sort Van den Broucke, Evelyne
collection PubMed
description In 2020, EUCAST introduced breakpoints for temocillin. Based on these guidelines, reporting of temocillin susceptibility of Enterobacterales in the context of complicated urinary tract infections (cUTI) implicates the use of a high dose of temocillin (2 g q8h) constantly. We aimed to evaluate the clinical outcome of patients treated with the standard dose (4 g/day) of temocillin in outpatient parenteral antimicrobial therapy (tOPAT). Demographics, clinical and treatment parameters, and late clinical cure (at day 30 after tOPAT completion) were recorded. Univariate generalised estimating equation analyses, with clinical cure as outcome variable, were performed to evaluate covariate associations. Fifty-seven tOPAT episodes in 50 patients were included with a median antimicrobial treatment duration of 21 (range 10–228) days, and cUTI was the main indication (87.7%). Late clinical cure was achieved in 85.7% of the tOPAT episodes. Non-disseminated infections and minimal inhibitory concentrations (MIC) values ≤ 8 mg/L were associated with good late clinical outcome. In conclusion, a standard temocillin dose (4 g/day) results in good clinical outcomes in the treatment of cUTIs in tOPAT patients. Therefore, our centre concluded that the use of standard temocillin dosing should be continued instead of the high dose for cUTI in non-critically ill patients infected with Enterobacterales with an MIC ≤ 4 mg/L.
format Online
Article
Text
id pubmed-9699557
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96995572022-11-26 Clinical Efficacy of Temocillin Standard Dosing in Patients Treated with Outpatient Antimicrobial Therapy Van den Broucke, Evelyne Thijs, Lore Desmet, Stefanie Vander Elst, Lotte Gijsen, Matthias Mylemans, Marnix Van de Gaer, Otto Peetermans, Willy E. Quintens, Charlotte Spriet, Isabel Pharmaceutics Article In 2020, EUCAST introduced breakpoints for temocillin. Based on these guidelines, reporting of temocillin susceptibility of Enterobacterales in the context of complicated urinary tract infections (cUTI) implicates the use of a high dose of temocillin (2 g q8h) constantly. We aimed to evaluate the clinical outcome of patients treated with the standard dose (4 g/day) of temocillin in outpatient parenteral antimicrobial therapy (tOPAT). Demographics, clinical and treatment parameters, and late clinical cure (at day 30 after tOPAT completion) were recorded. Univariate generalised estimating equation analyses, with clinical cure as outcome variable, were performed to evaluate covariate associations. Fifty-seven tOPAT episodes in 50 patients were included with a median antimicrobial treatment duration of 21 (range 10–228) days, and cUTI was the main indication (87.7%). Late clinical cure was achieved in 85.7% of the tOPAT episodes. Non-disseminated infections and minimal inhibitory concentrations (MIC) values ≤ 8 mg/L were associated with good late clinical outcome. In conclusion, a standard temocillin dose (4 g/day) results in good clinical outcomes in the treatment of cUTIs in tOPAT patients. Therefore, our centre concluded that the use of standard temocillin dosing should be continued instead of the high dose for cUTI in non-critically ill patients infected with Enterobacterales with an MIC ≤ 4 mg/L. MDPI 2022-10-25 /pmc/articles/PMC9699557/ /pubmed/36365108 http://dx.doi.org/10.3390/pharmaceutics14112289 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Van den Broucke, Evelyne
Thijs, Lore
Desmet, Stefanie
Vander Elst, Lotte
Gijsen, Matthias
Mylemans, Marnix
Van de Gaer, Otto
Peetermans, Willy E.
Quintens, Charlotte
Spriet, Isabel
Clinical Efficacy of Temocillin Standard Dosing in Patients Treated with Outpatient Antimicrobial Therapy
title Clinical Efficacy of Temocillin Standard Dosing in Patients Treated with Outpatient Antimicrobial Therapy
title_full Clinical Efficacy of Temocillin Standard Dosing in Patients Treated with Outpatient Antimicrobial Therapy
title_fullStr Clinical Efficacy of Temocillin Standard Dosing in Patients Treated with Outpatient Antimicrobial Therapy
title_full_unstemmed Clinical Efficacy of Temocillin Standard Dosing in Patients Treated with Outpatient Antimicrobial Therapy
title_short Clinical Efficacy of Temocillin Standard Dosing in Patients Treated with Outpatient Antimicrobial Therapy
title_sort clinical efficacy of temocillin standard dosing in patients treated with outpatient antimicrobial therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699557/
https://www.ncbi.nlm.nih.gov/pubmed/36365108
http://dx.doi.org/10.3390/pharmaceutics14112289
work_keys_str_mv AT vandenbrouckeevelyne clinicalefficacyoftemocillinstandarddosinginpatientstreatedwithoutpatientantimicrobialtherapy
AT thijslore clinicalefficacyoftemocillinstandarddosinginpatientstreatedwithoutpatientantimicrobialtherapy
AT desmetstefanie clinicalefficacyoftemocillinstandarddosinginpatientstreatedwithoutpatientantimicrobialtherapy
AT vanderelstlotte clinicalefficacyoftemocillinstandarddosinginpatientstreatedwithoutpatientantimicrobialtherapy
AT gijsenmatthias clinicalefficacyoftemocillinstandarddosinginpatientstreatedwithoutpatientantimicrobialtherapy
AT mylemansmarnix clinicalefficacyoftemocillinstandarddosinginpatientstreatedwithoutpatientantimicrobialtherapy
AT vandegaerotto clinicalefficacyoftemocillinstandarddosinginpatientstreatedwithoutpatientantimicrobialtherapy
AT peetermanswillye clinicalefficacyoftemocillinstandarddosinginpatientstreatedwithoutpatientantimicrobialtherapy
AT quintenscharlotte clinicalefficacyoftemocillinstandarddosinginpatientstreatedwithoutpatientantimicrobialtherapy
AT sprietisabel clinicalefficacyoftemocillinstandarddosinginpatientstreatedwithoutpatientantimicrobialtherapy